INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 48 filers reported holding INOZYME PHARMA INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $410,029 | +32.6% | 97,626 | +75.9% | 0.00% | – |
| Q2 2023 | $309,152 | +367.2% | 55,503 | +380.6% | 0.00% | – |
| Q1 2023 | $66,170 | +787.0% | 11,548 | +62.5% | 0.00% | – |
| Q4 2022 | $7,460 | -6.8% | 7,105 | +142.7% | 0.00% | – |
| Q3 2022 | $8,000 | – | 2,927 | +41714.3% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 7 | -99.9% | 0.00% | – |
| Q1 2022 | $28,000 | -65.4% | 6,647 | -43.9% | 0.00% | – |
| Q4 2021 | $81,000 | +1925.0% | 11,853 | +4030.0% | 0.00% | – |
| Q3 2021 | $4,000 | -90.7% | 287 | -88.5% | 0.00% | – |
| Q2 2021 | $43,000 | -81.4% | 2,504 | -78.5% | 0.00% | – |
| Q1 2021 | $231,000 | +5675.0% | 11,658 | +6412.8% | 0.00% | – |
| Q4 2020 | $4,000 | -66.7% | 179 | -63.2% | 0.00% | – |
| Q3 2020 | $12,000 | – | 487 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $10,852,000 | 4.54% |
| CHI Advisors LLC | 892,057 | $6,084,000 | 2.02% |
| Sofinnova Investments, Inc. | 2,028,308 | $13,833,000 | 0.81% |
| MPM BioImpact LLC | 302,615 | $2,064,000 | 0.38% |
| NEA Management Company, LLC | 2,444,379 | $16,671,000 | 0.34% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,344,786 | $15,991,000 | 0.34% |
| Rock Springs Capital Management LP | 868,466 | $5,923,000 | 0.14% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,013,216 | $6,910,000 | 0.13% |
| Orbimed Advisors | 526,600 | $3,591,000 | 0.05% |
| Overbrook Management Corp | 16,726 | $114,000 | 0.02% |